Licensing status

Publication and contact information



V-region immunoglobulin-containing suppressor of T cell activation (VISTA)

Cell culture and mouse studies suggest inhibiting VISTA could help treat cancer. In cultured human CD4+ and CD8+ T cells, a VISTA-Ig fusion protein decreased anti-CD3 mAb-induced T cell
proliferation compared with control Ig. In multiple mouse xenograft tumor models, a VISTA mAb decreased tumor growth and increased the number of effector T cells in the tumor compared with control antibody. In a mouse model of melanoma, the VISTA mAb increased T cell tumor infiltration compared with control antibody and delayed tumor progression. Next steps include testing anti-VISTA mAbs alone or in combination with other therapeutics in additional tumor models.

SciBX 7(18); doi:10.1038/scibx.2014.521
Published online May 8, 2014

Findings from both studies patented; licensed to ImmuNext Inc. and Johnson & Johnson

Lines, J.L. et al. Cancer Res.; published online April 1, 2014;
Contact: J. Louise Lines, King's College London, London, U.K.

Le Mercier, I. et al. Cancer Res.; published online April 1, 2014;
Contact: Li Wang, Geisel School of Medicine at Dartmouth, Lebanon, N.H.